Indian biopharmaceutical major Biocon Biologics on Monday said that private equity fund True North will acquire a 2.44% stake in the company for ₹536.25 crore, or around $75 million.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
